|
WO2020222892A1
|
|
Treatment of headache using anti-cgrp antibodies
|
|
TW202030205A
|
|
Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
|
|
TW202039549A
|
|
Acute treatment and rapid treatment of headache using anti-cgrp antibodies
|
|
KR20190005874A
|
|
Humanized anti-PACAP antibodies and uses thereof
|
|
AU2016250478A1
|
|
Antibodies to IL-6 and use thereof
|
|
CA2982856A1
|
|
Anti-pacap antibodies and uses thereof
|
|
EP3244738A1
|
|
Anti-glycoprotein antibodies and uses thereof
|
|
TW201629098A
|
|
Humanized anti-ACTH antibodies and use thereof
|
|
US2015259414A1
|
|
Anti-ACTH antibodies and use thereof
|
|
WO2015054293A1
|
|
Anti-il-6 antibodies for the treatment of psoriatic arthritis
|
|
CA2916980A1
|
|
Regulation of glucose metabolism using anti-cgrp antibodies
|
|
US2016033504A1
|
|
Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
|
|
MX2015011968A
|
|
Temperature shift for high yield expression of polypeptides in yeast and other transformed cells.
|
|
EP2964673A2
|
|
Antibodies to hgf and compositions containing
|
|
AU2013203976A1
|
|
Antibodies to IL-6 and use thereof
|
|
AU2013203892A1
|
|
Antagonists of IL-6 to prevent or treat thrombosis
|
|
AU2013203879A1
|
|
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue and/or fever
|
|
AU2013203851A1
|
|
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
CA2821515A1
|
|
Anti-ngf compositions and use thereof
|
|
MX2012005927A
|
|
Antibodies to il-6 and use thereof.
|
